Xylometazoline HCl
| Status | Commercial |
| Development phase | |
| Therapeutic cat. | Other |
| Polymorphic form | Substance does not show polymorphism |
| CAS No. | 1218-35-5 |
| Reference Product | |
| Injectable Form | |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | |
| Samples |
Drug description
Xylometazoline, an imidazoline derivative, exhibits sympathomimetic and nasal decongestant properties. It functions by binding to alpha (α)-adrenergic receptors, leading to the vasoconstriction of nasal blood vessels.
Available as over-the-counter (OTC) nasal sprays or drops, Xylometazoline provides temporary relief from nasal congestion caused by colds, hay fever, or other respiratory allergies.
Polpharma API
- Extensive production experience
- Product meeting the highest quality standards (all single impurities below 0,05%)
- All intermediates produced in-house
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
